Skip to content

Tao Li

11 papers in the library · 85 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Remodeling of the ventral attention network-default mode network as potential neural correlates of anxiety in lumbar disc herniation patients treated with lever positioning manipulation: a resting-state fMRI study.

BMC Complementary Medicine and Therapies March 16, 2026 Xing-Chen Zhou, Shuang Wu, Kai-Zheng Wang et al.

OBJECTIVE: To analyze the brain functional network remodeling associated with the relief of negative emotions in patients with lumbar disc herniation (LDH) treated with lever positioning manipulation (LPM) using resting-state fMRI (rs-fMRI) technology. METHODS: A prospective study included LDH patients (Group 1, n = 47) and age- and gender-matched healthy controls (Group 2, n = 43). Group 1...

Effectiveness of mindfulness-based cognitive therapy for treating generalized anxiety disorder and the moderating influence of abuse during childhood: A randomized controlled trial.

Journal of Affective Disorders June 15, 2025 Guangzheng Tang, Bijun Chen, Manhua Wu et al.

Mindfulness-based cognitive therapy (MBCT) has emerged as a promising intervention for generalized anxiety disorder (GAD). This study evaluated MBCT's effectiveness for GAD and examined whether childhood maltreatment moderates its impact. Individuals with GAD were randomized to receive one of two 8-week interventions, either MBCT in-person or psychoeducation on-line (n = 27 per group). At...

Molecular Mechanisms and Toxic Effects of Ketamine.

Fa yi xue za zhi April 25, 2025 Yu-Meng Zuo, Wei Han, Jian-Bo Zhang et al.

Ketamine is a dissociative anesthetic. It is clinically used as a surgical anesthetic or anesthetic inducer and has a certain degree of mental dependence. Its abuse can lead to nerve damage, adverse emotional reactions and other toxic side effects. The primary mechanism by which ketamine exerts its pharmacological effects is to block N-methyl-D-aspartate receptors (NMDAR). It also functions...

Ketamine reverses chronic corticosterone-induced behavioral deficits and hippocampal synaptic dysfunction by regulating eIF4E/BDNF signaling.

Neuropharmacology December 15, 2024 Canyu Yang, Tahir Ali, Axiang Li et al. 11 citations

Major depressive disorder (MDD) is a debilitating illness with a high global burden. While Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, offers rapid-acting antidepressant effects, its mechanism remains incompletely understood. Recent research suggests that dysregulation of mRNA translation via the Eukaryotic initiation factor 4E (eIF4E) pathway might contribute to depression...

New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR.

Talanta April 1, 2023 Chun-Hui Song, Wei Jia, Cui-Mei Liu et al. 14 citations

For the first time, the identification and quantification of trace level of new psychoactive substances (NPS) in a complex chocolate matrix have been reported. Since the beginning of 2022, suspected NPS-infused chocolate samples confiscated in inbound packages have been continuously sent to our laboratory for analysis. The qualitative gas chromatography-mass spectrometry (GC-MS) results were...

Psilocin suppresses methamphetamine‐induced hyperlocomotion and acquisition of conditioned place preference via D2R‐mediated ERK signaling

CNS Neuroscience & Therapeutics January 10, 2023 Jing Wang, Min Liang, Qing Shang et al. 23 citations

Abstract Aim Psilocin is an active metabolite form of psilocybin and exerts psychoactive effects. Recent studies suggest that psilocin may have regulatory effects on abuse drugs, but the mechanisms remain unclear. In this study, we want to explore the effects of psilocin on methamphetamine (METH)‐induced alterations of behavior in mice and its molecular mechanisms. Methods Acute METH...

Chronic lithium treatment ameliorates ketamine-induced mania-like behavior via the PI3K-AKT signaling pathway

Zoological Research November 18, 2022 Rongjun Ni, Tianhao Gao, Yi-Yan Wang et al.

Ketamine, a rapid-acting antidepressant drug, has been used to treat major depressive disorder and bipolar disorder (BD). Recent studies have shown that ketamine may increase the potential risk of treatment-induced mania in patients. Ketamine has also been applied to establish animal models of mania. At present, however, the underlying mechanism is still unclear. In the current study, we found...

Body-mind relaxation meditation modulates the thalamocortical functional connectivity in major depressive disorder: a preliminary resting-state fMRI study.

Translational Psychiatry October 23, 2021 Fangfang Chen, Xueyu Lv, Jiliang Fang et al.

Mindfulness-based interventions such as meditation have increasingly been utilized for the treatment of psychological disorders and have been shown to be effective in the treatment of depression and relapse prevention. However, it remains largely unclear the neural mechanism of the therapeutic effects of meditation among depressed individuals. In this study, we investigated how body-mind...

Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice.

Pharmacology, Biochemistry and Behavior January 12, 2021 Tianhao Gao, Rongjun Ni, Shasha Liu et al.

Ketamine, a dissociative anaesthetic, has been used in the treatment of major depressive disorder (MDD) as a rapid acting antidepressant drug. Recent studies have shown that ketamine may increase the potential risk of treatment-induced mania in MDD patients. Lithium is a well-known mood stabilizer and has been widely used for the treatment of mania. It is not fully understood which forebrain...

A microdosing approach for characterizing formation and repair of carboplatin–DNA monoadducts and chemoresistance

International Journal of Cancer December 2, 2010 Paul T. Henderson, Tao Li, Miaoling He et al. 37 citations

Formation and repair of platinum (Pt)-induced DNA adducts is a critical step in Pt drug-mediated cytotoxicity. Measurement of Pt-DNA adduct kinetics in tumors may be useful for better understanding chemoresistance and therapeutic response. However, this concept has yet to be rigorously tested because of technical challenges in measuring the adducts at low concentrations and consistent access to...

Abstract 3522: A Phase 0 microdosing trial to identify chemoresistance: From bench to bedside

Cancer Research April 15, 2010 Sisi Wang, Miaoling He, Tao Li et al.

Abstract BACKGROUND: DNA damage is the critical step in cancer cell response to platinum (Pt) chemotherapy. We hypothesize that low levels of Pt-induced DNA damage are predictive of chemoresistance. Accelerator mass spectrometry (AMS) is an ultrasensitive method for measuring radiocarbon. By measuring 14C bound to DNA, AMS can detect carboplatin-induced DNA damage after patients receive one...